Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)

• US 7,160,727 B2
• Filed: 11/19/2004
• Issued: 01/09/2007
• Est. Priority Date: 11/20/2003
• Status: Active Grant

• Current Assignee: University of Iowa Research Foundation
• Original Assignee: University of Iowa Research Foundation
• Inventors: Stein, Colleen, McCray, Paul B. Jr., Davidson, Beverly L.
• Primary Examiner(s): Guzo; David
• Application Number:
  US10/993,319
• Publication Number:
  US 20050123517A1
• Time in Patent Office: 781 Days
• Field of Search: None
• US Class Current: 435/456
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2740/15043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2740/15045 Special targeting system for viral vectors
• CPC Class Codes: C12N 2760/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2810/6072 negative strand RNA viruses

Abstract

The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy.

Claims

1. A method for transducing a nervous system cell with a transgene comprising contacting the cell with a pseudotyped retrovirus virion comprising a Lymphocytic Choriomeningitis Virus strain WE-54 envelope glycoprotein and the transgene, wherein the envelope glycoprotein comprises a phenylalanine at residue 260.

3. The method of claim 1, wherein the envelope glycoprotein further comprises a phenylalanine at residue 153.

4. The method of claim 1, wherein said retrovirus virion is a lentivirus virion.

6. The method of claim 4, wherein said lentivirus virion is a feline immunodeficiency virus virion.

11. The method of claim 4, wherein said lentivirus virion is a feline immunodeficiency virus virion.

2. A method for transducing a nervous system cell with a transgene comprising contacting the cell with a pseudotyped retrovirus virion comprising a Lymphocytic Choriomeningitis Virus strain WE-54 envelope glycoprotein and the transgene, wherein the envelope glycoprotein comprises a phenylalanine at residue 153.

5. The method of claim 2, wherein said retrovirus virion is a lentivirus virion.

7. A method for transducing a nervous system cell with a transgene, said method comprising contacting the nervous system cell with a vector comprising (a) a nucleic acid encoding an envelope glycoprotein from Lymphocytic Choriomeningitis Virus strain WE-54, and (b) the transgene.

8. The method of claim 7, wherein the envelope glycoprotein comprises a phenylalanine at residue 260.

9. The method of claim 7, wherein the envelope glycoprotein comprises a phenylalanine at residue 153.

10. The method of claim 7, wherein the envelope glycoprotein comprises a phenylalanine at residue 260 and a phenylalanine at residue 153.